The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Hisako OnoYoshihiro SowaMano HorinakaYosuke IizumiMotoki WatanabeMie MoritaEmi NishimotoTetsuya TaguchiToshiyuki SakaiPublished in: Breast cancer research and treatment (2018)
We found that the combination of OBP-801 and eribulin synergistically inhibited the growth with apoptosis in TNBC cells, suggesting that this combination might be a promising novel strategy for treating TNBC patients.
Keyphrases
- histone deacetylase
- cell cycle arrest
- end stage renal disease
- oxidative stress
- breast cancer cells
- induced apoptosis
- ejection fraction
- newly diagnosed
- metastatic breast cancer
- cell death
- chronic kidney disease
- endoplasmic reticulum stress
- pi k akt
- prognostic factors
- clinical trial
- phase ii
- cell proliferation
- patient reported